 Download PDF
|
| Market: Hong Kong | Ticker: 690 | ISIN: KYG9198H1406 | Industry: Healthcare |
Uni-Bio Science Group is a leading Chinese biopharmaceutical healthcare company focusing on the four strategic areas of bio-innovative drugs, high-value generic drugs, medical cosmetology, and CMO, integrating R&D, production and sales. The Company is focused on addressing high unmet medical needs via the development and commercialisation of highly innovative therapies.
Led by a highly experienced management team and Board of Directors with broad international pharmaceutical and commercial experience, Uni-Bio Science Group Ltd was founded in 2001 and is listed on the Hong Kong Stock Exchange (Stock Code: 0690).
Uni-Bio Science Group Ltd has developed unparalleled expertise in the research, development and manufacturing of pharmaceuticals to world-class standards. The Group leverages its broad commercial presence in China for its proprietary portfolio of marketed pharmaceutical products and the products of its partners.
Key Products
Uni-Bio is built upon the vision of addressing the pressing needs in the provision of high-quality Chinese healthcare solutions.
Uni-Bio has a growing pipeline of novel treatments and marketed products which demonstrate strong therapeutic advantages for patients in the disease areas most in need of new solutions to growing healthcare problems – endocrinology, ophthalmology, dermatology and medical cosmetology.
Led by a highly experienced management team and Board of Directors with broad international pharmaceutical and commercial experience, Uni-Bio Science Group Ltd was founded in 2001 and is listed on the Hong Kong Stock Exchange (Stock Code: 0690).
Uni-Bio Science Group Ltd has developed unparalleled expertise in the research, development and manufacturing of pharmaceuticals to world-class standards. The Group leverages its broad commercial presence in China for its proprietary portfolio of marketed pharmaceutical products and the products of its partners.
Key Products
Uni-Bio is built upon the vision of addressing the pressing needs in the provision of high-quality Chinese healthcare solutions.
Uni-Bio has a growing pipeline of novel treatments and marketed products which demonstrate strong therapeutic advantages for patients in the disease areas most in need of new solutions to growing healthcare problems – endocrinology, ophthalmology, dermatology and medical cosmetology.
| Marketed products | Lead clinical development programs |
|
|
Expansion Strategy
China’s well-documented ageing population and growing population places great strain on our healthcare systems, however Uni-Bio has built broad capability to address this challenge both in the breadth of its product portfolio and experienced commercial function.
Uni-Bio is focused on delivering against its strategic priorities to achieve sustainable growth for the Group:
China’s well-documented ageing population and growing population places great strain on our healthcare systems, however Uni-Bio has built broad capability to address this challenge both in the breadth of its product portfolio and experienced commercial function.
Uni-Bio is focused on delivering against its strategic priorities to achieve sustainable growth for the Group:
-
To grow its diversified portfolio of innovative treatments and healthcare solutions through partnerships that address high unmet medical need to patients in China;
-
To realise the broad growth opportunities presented by the changing dynamic of the Chinese healthcare market which favour Uni-Bio’s focus on innovation;
- Through enhancing product quality and effectively reduce cost, it brings much more better drug with economical price, so to boost the sales;
-
To increase the breadth of its sales coverage beyond the key provinces where the Company already has a strong geographic footprint.
Uni-Bio’s ultimate goal is to build a leading, sustainable organization that builds and delivers shareholder value by efficiently executing a number of growth strategies.
| Share Data | 20/03/2023 | ||
|---|---|---|---|
| Currency | HKD | Volume | 1,921,200 |
| Previous Close | 0.057 | Number of Shares | 6,364,768,147 |
| Change (%) | -1.72 | Market Cap (mil) | 362.79 |
Notes:
(1) Ratio equals to total liabilities/total equity. |
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Uni-Bio Science Group Ltd Unit 502, 5/F, No. 20 Science Park East Avenue, Hong Kong Science Park, Shatin, Hong Kong Telephone: (852) 31023232 E-mail: ir@uni-bioscience.com |
Supplied by ©
Euroland.com
|
| Share Data | 20/03/2023 |
|---|---|
| Currency | HKD |
| Previous Close | 0.057 |
| Change (%) | -1.72 |
| Volume | 1,921,200 |
| Number of Shares | 6,364,768,147 |
| Market Cap (mil) | 362.79 |
| Key Figures (HK$’000) | 12M 2019 | 12M 2020 | 12M 2021 |
|---|---|---|---|
| For the year ended 31 December | |||
| Revenue | 209,449 | 208,776 | 353,405 |
| Gross profit | 181,517 | 181,094 | 277,007 |
| L/EBITA | 27,376 | (21,703) | 13,666 |
| (Loss)/Profit for the year | 2,459 | (71,319) | (19,591) |
| As at 31 December | |||
| Total assets | 296,453 | 252,717 | 267,593 |
| Total liabilities | 55,003 | 63,306 | 93,286 |
| Total equity | 241,450 | 189,411 | 174,307 |
| Total fixed assets | 42,320 | 51,094 | 43,888 |
| Earnings Per Share (HK cents) | |||
| Basic | 0.04 | (1.11) | (0.31) |
| Diluted | 0.04 | (1.11) | (0.31) |
| Financial Indicators | |||
| Gross profit margin (%) | 86.7 | 86.7 | 78.4 |
| Current ratio (times) | 3.53 | 3.01 | 2.18 |
| Total liabilities to total asset ratio (%) | 18.6 | 25.1 | 34.9 |
| Debt to equity ratio(1) (%) | 22.8 | 33.4 | 53.5 |
Notes:
(1) Ratio equals to total liabilities/total equity.
(1) Ratio equals to total liabilities/total equity.